Current management of non-alcoholic fatty liver disease

Comparison of aerobic and combined aerobic and whole-body vibration training effects on physical fitness in non-alcoholic fatty liver patients

The aim of this study was to evaluate the effectiveness of exercises with whole-body vibration which was added to aerobic training on the physical fitness of patients with non-alcoholic fatty liver disease. Thirty-two patients diagnosed with non-alcoholic fatty liver (age 44.39±8.74 years) were randomly divided into an aerobic training + vibration group and an aerobic training + sham vibration group. The aerobic training was continued at 60-80% heart rate workload, 40 min per day during 3 days per week, for 8 weeks. Vibration were performed with dynamic and static exercises at 30 Hz, with a 2 mm amplitude, for 15 min. The energy expenditure responses were carried out by an exercise tolerance test system. Lower limb isometric muscle strength assessment was made with a calibrated handheld dynamometer from bilaterally knee extensors. The sit to stand test, and the time up and go test were used for physical performance evaluation. At eight weeks, both groups showed a significant reduction in the sit to stand (-1.62±1.00 vs -0.37±1.52), the time up and go test (-1.43±0.99 vs -1.39±1.06), the right lower extremity muscle strength (1.01±1.61 vs 1.22±2.82), and the energy expenditure scores (MET; 1.88 ml/kg/min, 95% confidence interval (CI) 1.19; 2.57, d=0.55, minimal clinically important difference (McID) = 0.69 vs 2.01 ml/kg/min, 95% CI 0.76; 3.24, d=0.26, McID = 1.54, respectively), however no significant differences emerged between groups (P≥0.05). The addition of vibration exercises to an aerobic program did not provide additional benefits to physical fitness in patients with non-alcoholic fatty liver.

Free radicals, antioxidants, nuclear factor-E2-related factor-2 and liver damage

Oxidative/nitrosative stress is proposed to be a critical factor in various diseases, including liver pathologies. Antioxidants derived from medicinal plants have been studied extensively and are relevant to many illnesses, including liver diseases. Several hepatic disorders, such as viral hepatitis and alcoholic or nonalcoholic steatohepatitis, involve free radicals/oxidative stress as agents that cause or at least exacerbate liver injury, which can result in chronic liver diseases, such as liver fibrosis, cirrhosis and end-stage hepatocellular carcinoma. In this scenario, nuclear factor-E2-related factor-2 (Nrf2) appears to be an essential factor to counteract or attenuate oxidative or nitrosative stress in hepatic cells. In fact, a growing body of evidence indicates that Nrf2 plays complex and multicellular roles in hepatic inflammation, fibrosis, hepatocarcinogenesis and regeneration via the induction of its target genes. Inflammation is the most common feature of chronic liver diseases, triggering fibrosis, cirrhosis and hepatocellular carcinoma. Increasing evidence indicates that Nrf2 counteracts the proinflammatory process by modulating the recruitment of inflammatory cells and inducing the endogenous antioxidant response of the cell. In this review, the interactions between antioxidant and inflammatory molecular pathways are analyzed.

Association of Pro-inflammatory Dietary Intake and Non-Alcoholic Fatty Liver Disease: Findings from Iranian case-control study

Background: Non-Alcoholic Fatty Liver Disease (NAFLD) is considered as a major health problem in the world. There is much evidence that diet and dietary factors play an important role in inflammation, and consequently pathogenesis of NAFLD. To investigate the role of diet in the development of inflammation, we can use the Dietary Inflammatory Index (DII), which has been shown to be predictive of levels of inflammatory markers. Methods: 295 incident cases were selected using the convenience-sampling procedure, and 704 controls randomly were selected from the same clinic and among the patients who had no hepatic steatosis and were frequency-matched on age (±5 years) and sex. The DII was computed based on dietary intake from 168-item FFQ. Logistic regression models were used to estimate multivariable ORs. Results: Subjects in tertile 3 had 1.57 (95% CI: 1.13-2.20), 1.78 (95% CI: 1.19-2.67), and 2.02 (95% CI: 1.32-3.09) times higher odds of developing NAFLD, compared to subjects in tertile 1 in models 1 (adjusted for age), 2 (model 1 + BMI, education, smoking, alcohol, diabetes, low density lipoprotein, triglycerides) and 3 (model 2 + aspartate transaminase/alanine transaminase), respectively. When used as a continuous variable, one unit increase in DII was associated with 1.16 (95% CI: 1.05, 1.29), 1.21 (95% CI: 1.107, 1.37) and 1.25 (95% CI: 1.10, 1.43) increase in odds of NAFLD in models one, 2 and 3 respectively. Conclusion: Subjects who consumed a more pro-inflammatory diet were at increased odds of NAFLD.

A study on the mechanism of adipokine in non-alcoholic fatty liver in rats treated by four herbs decoction

The objective of the study is to determine adipokine-associated mechanism of efficacy of Si He Decoction (SHD) for treating non-alcoholic fatty liver disease (NAFLD). Forty-five Sprague-Dawley (SD) rats were randomly divided into control group, model group, SHD low-dose group, SHD middle-dose group, and SHD high-dose group. Except control group, others were fed with a high-fat diet for 12 weeks to establish model. Then, H&E and oil red O staining were performed, and enzyme-linked immunosorbent assay (ELISA) was used to detect expression level of adipokine-associated molecules. H&E and oil red O staining results revealed that SHD treatment for NAFLD could effectively improve liver pathological conditions compared to that in model group, and the best efficacy was observed in SHD high-dose group. Compared to model group, SHD treatment could effectively downregulate expression level of tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6), and upregulate expression level of visfatin, adiponectin (APN), leptin (LEP), and resistin in NAFLD rats. SHD can improve NAFLD through multiple means of targeting adipokines.

Association between dietary total antioxidant capacity and hepatocellular ballooning in nonalcoholic steatohepatitis: a cross-sectional study

PURPOSE

Nonalcoholic steatohepatitis (NASH) is characterized by steatosis, lobular inflammation, ballooning, and in some cases, fibrosis, which can progress to cirrhosis and carcinoma. The progression of NASH is closely related to oxidative stress. Dietary intake of antioxidants has been suggested in protection against oxidative damage and related clinical complications. Thus, we evaluated the potential association of dietary total antioxidant capacity (TAC) with disease severity in NASH patients, as well as with anthropometric and body composition markers and biochemical parameters.

METHODS

Thirty-three outpatients with a mean age of 48.4 ± 1.9 years were evaluated. Dietary TAC was estimated from a quantitative food frequency questionnaire. NASH severity, determined by liver biopsy, lifestyle characteristics, occurrence of comorbidities, anthropometry, body composition, and biochemical parameters were assessed.

RESULTS

NASH patients who had a higher dietary TAC had fewer ballooned hepatocytes compared to those with a lower TAC (p = 0.024). The patients with the highest dietary TAC had a reduction of approximately 20% in the risk of having many ballooned hepatocytes (OR 0.791; 95% CI 0.643-0.974; p = 0.027). There was no association of steatosis, lobular inflammation, and fibrosis with dietary TAC. The same occurred for lifestyle characteristics, occurrence of comorbidities, anthropometry, body composition, and biochemical parameters.

CONCLUSION

Dietary TAC is higher in patients with lower hepatic injury (ballooning), suggesting a possible role of food intake naturally high in its antioxidant capacity in reducing free radical production and, consequently, oxidative stress.

The Utility of Noninvasive Scores in Assessing the Prevalence of Nonalcoholic Fatty Liver Disease and Advanced Fibrosis in Type 2 Diabetic Patients

GOALS

The aim of our study is to assess the prevalence of nonalcoholic fatty liver disease (NAFLD) and advanced hepatic fibrosis in patients with type 2 diabetes mellitus (T2DM) using simple noninvasive scores.

BACKGROUND

In individuals with T2DM, there is a very high prevalence of NAFLD. Moreover, T2DM is a risk factor for advanced disease in NAFLD patients.

STUDY

Using International Classification of Diseases, Ninth Revision codes all patients with the diagnosis of T2DM were reviewed and a retrospective chart analysis was performed on 169,910 patients between the ages of 18 to 80. To predict the prevalence of NAFLD, we calculated the hepatic steatosis index. To estimate the prevalence of advanced fibrosis, NAFLD fibrosis score (NFS), fibrosis-4 index, aspartate aminotransferase (AST) to platelet ratio index (APRI), and AST/alanine aminotransferase (ALT) ratio were calculated.

RESULTS

Of the 121,513 patients included in the analysis, 89.4% were above normal weight limit. NAFLD based on Hepatic Steatosis Index>36 was present in 87.9% of patients. Advanced fibrosis was present in 35.4% based on NFS>0.676, 8.4% based on fibrosis-4>2.67, 1.9% based on APRI>1.5, and 16.9% based on AST/ALT>1.4% indicating advanced fibrosis and high risk of developing cirrhosis related to NAFLD.

CONCLUSIONS

In this large cohort of patients with T2DM, we detected high prevalence of hepatic steatosis and advanced fibrosis using noninvasive scores. These scores are easy and nonexpensive tools to screen for NAFLD and advanced fibrosis, although the significant variability of the percentage of patients with advanced fibrosis using these scores indicates the need for further validation in diabetic populations.

Protective effect of Hua Tan Qu Shi decoction against liver injury in rats with nonalcoholic fatty liver disease

BACKGROUND

Nonalcoholic fatty liver disease (NAFLD), is currently a worldwide health problem. None of the existing treatment medications had got a satisfactory effect. Hua Tan Qu Shi (HTQS) decoction is a Chinese herbal formula, which has been used clinically to treat NAFLD for years. However, the underlying mechanisms are still unclear.

METHODS

High-fat diet (HFD) induced non-alcoholic fatty liver disease rats treated with or without HTQS decoction by gavage for 10 weeks and examined by serology, 24-h albuminuria, histology, immunohistochemistry, and molecular analyses.